Skip to main content
padlock icon - secure page this page is secure

Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents

Buy Article:

$36.50 + tax (Refund Policy)

Omalizumab, a monoclonal anti‐immunoglobulin E (IgE) antibody, is being successfully used as supplementary therapy to improve asthma control in children with severe persistent allergic asthma from the age of ≥6 years. Because the majority of commercially available IgE assays measure free as well as omalizumab-bound IgE, a rise in total IgE is believed to occur in the course of therapy. We aimed at testing the therapeutic monitoring regime based on total IgE measurements in patients treated with omalizumab over a period of 12‐60 months. We report on 10 patients aged 8‐17 years who were given omalizumab to treat severe allergic bronchial asthma. Total IgE in serum (sandwich immunoassay ADVIA Centaur; Siemens Healthcare Diagnostics GmbH, Eschborn, Germany) was determined before injection of omalizumab. In two patients, the dose of omalizumab was reduced during the treatment once the patients' total IgE was in the normal range. Six months after the start of treatment with omalizumab, all patients showed a marked drop in total IgE levels compared with baseline (p < 0.003). All patients tolerated omalizumab well. The dose reduction in two patients with normal total IgE levels caused no clinical deterioration. The rise in total IgE levels after treatment with omalizumab, which has been reported in the literature, was not confirmed in the present study. Extensive elimination of IgE by omalizumab influences the immune system and IgE regulation. This will be an important aspect of dosage in long-term therapy. Patients undergoing treatment with omalizumab must be monitored at close intervals.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Allergy; anti-IgE; asthma; immunoglobulin E; monoclonal antibody; omalizumab; therapeutic monitoring

Document Type: Research Article

Affiliations: Department of Pediatrics, Pediatric Pulmonology, and Allergy, Justus-Liebig University, Giessen, Germany

Publication date: January 1, 2012

More about this publication?
  • Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

    The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.

    Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

    Articles marked "F" offer free full text for personal noncommercial use only.

    The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
  • Editorial Board
  • Information for Authors
  • Submit a Paper
  • Information for Advertisers
  • Reprint Requests
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more